Physician profile
Srinivas N Paranandi
NPI 1013909258
$2,157.16
in general payments reported to CMS, 2019-2025
19 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $24.79 · 2021: $131 · 2022: $255 · 2023: $410 · 2024: $692 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $473.22 | 2020-2024 | Flexability, Aveir, Assurity |
| Boston Scientific Corporation | $207.90 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $170.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $153.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $142.18 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $129.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.72 | 2023 | Camzyos |
| Regeneron Pharmaceuticals, INC. | $122.81 | 2019 | |
| Abiomed | $117.80 | 2022 | |
| Cvrx, INC. | $112.40 | 2024 | Barostim Neo System |
| Novo Nordisk INC | $93.37 | 2023 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.03 | 2020-2023 | Lifevest |
| Pfizer INC. | $79.66 | 2023-2025 | |
| Medtronic, INC. | $34.92 | 2022-2025 | Symplicity G3 |
| Daiichi Sankyo INC. | $28.55 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $20.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.02 | 2019 | |
| Amgen INC. | $18.61 | 2021 | |
| Gilead Sciences, INC. | $16.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Paranandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.